TF-VIIa signaling promotes tumor growth. (A) Mab-10H10 does not influence proliferation on different matrices. MDA-MB-231mfp cells were grown on collagen I, laminin 5, or vitronectin and treated with Mab-10H10 or Mab-5G9 (left graph). Cells were also plated in 0.5% methylcellulose for anchorage-independent cell growth (right graph). Proliferation was determined using an MTT assay, and anchorage-independent survival was quantified by cell counts. Values are expressed as percentage of control cells. (B) MDA-MB-231mfp subcutaneous tumor growth in the presence of 1 mg of control IgG1 (TIB115), Mab-5G9, or Mab-10H10 coinjected to achieve high local antibody concentrations in the flanks of SCID mice. Tumor weights were determined at sacrifice (n = 6, 2-sided ANOVA, Kruskal-Wallis; **P < .001). (C) Tumor growth of M24met melanoma cells injected subcutaneously without or with 1 mg of Mab-5G9 or Mab-10H10 (n = 8, 2-sided ANOVA, Kruskal-Wallis; **P < .001; *P < .01). (D) MDA-MB-231mfp tumor growth is inhibited in the mammary fat pad by treatment with 1 mg of coinjected Mab-10H10; SFM denotes serum-free medium control (n = 6, *P < .01). (E) Results of histologic examination of orthotopic MDA-MB-231mfp tumors grown in the presence or absence of Mab-10H10. Hematoxylin and eosin and CD31 staining of 5-μm frozen sections are shown. CD31 positive vessels were quantified, *, difference in vessel density between groups, t test, P < .005.